Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...

Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...

Cognition Therapeutics (CGTX) announced that JamesGalvin, MD, MPH will present topline results from the ‘SHIMMER’ study of zervimesine in ...

Among patients with iRBD, altered visuospatial cue-elicited N2 and P3 ERPs predicted phenoconversion to α-synucleinopathies.

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

The symptoms of Parkinson’s disease could be reversed through injections of nanoparticles into the brain, which is a much ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

A once-a-day pill that could be the “holy grail” in the treatment of Alzheimer’s disease is a step closer to becoming a ...

( MENAFN - Mid-East Info) DUBAI, United Arab Emirates; January 2025 - Mayo clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

Caregivers need support and room to talk, as shown by Dana Reeve’s experience in “Super/Man: The Christopher Reeve Story.” ...

Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...